enteroviru
posit
singlestrand
rna
viru
belong
picornaviruda
famili
togeth
coxsackieviru
known
major
caus
agent
caus
mild
rash
symptom
call
handfootandmouth
diseas
hfmd
infant
children
sinc
signific
increas
epidem
observ
throughout
asianpacif
region
outbreak
taiwan
young
children
infect
approxim
children
hospit
sever
pulmonari
neurogen
complic
result
death
viral
drug
vaccin
develop
protect
efficaci
could
effici
evalu
due
lack
proper
anim
model
sever
anim
model
develop
infecti
model
use
mouseadapt
strain
innat
immunodefici
mice
monkey
model
intraperiton
ip
inject
clinic
isol
adult
mice
caus
appar
clinic
symptom
administr
mouseadapt
strain
icr
mice
caus
hind
limb
paralysi
lp
death
within
wk
challeng
challeng
balbc
icr
mice
infect
strain
also
lethal
defici
type
type
ii
ifn
receptor
mous
caus
neurolog
manifest
infect
nonmous
adapt
strain
brcr
strain
origin
prototyp
genotyp
strain
california
demonstr
induc
neurolog
manifest
tremor
ataxia
brain
edema
pulmonari
edema
pe
cardiac
failur
cynomolgu
monkey
model
perfect
hfmd
neuropathogenesi
caus
viral
pathogenesi
mouseadapt
newborn
suckl
mice
dose
mimic
human
infect
exhibit
restrict
timefram
one
week
old
mous
age
allow
pathogen
challeng
addit
innat
immun
particularli
type
ifn
involv
pathogen
phenotyp
report
end
recent
success
develop
transgen
mice
carri
known
human
receptor
scaveng
receptor
class
b
member
hfmdlike
skin
rash
observ
transgen
mice
preinfect
clinic
isol
genotyp
sever
limb
paralysi
death
transgen
mice
preinocul
clinic
isol
coxsackieviru
viral
load
tissu
cn
accompani
upregul
proinflammatori
mediat
correl
recruit
infiltr
lymphocyt
result
sever
diseas
transgen
mice
also
observ
patient
enceph
associ
pe
higher
mortal
rate
patient
brainstem
enceph
pe
might
caus
increas
pulmonari
vascular
permeabl
result
brainstem
lesion
caus
excess
releas
studi
investig
whether
mous
model
could
suitabl
evalu
protect
efficaci
confer
previous
describ
neutral
antibodi
administr
transgen
mice
reduc
develop
hair
loss
scurfi
skin
well
limb
paralysi
induc
infect
protect
sever
limb
paralysi
result
death
infect
protect
associ
reduct
viral
load
brain
spinal
cord
limb
muscl
also
associ
reduct
secret
proinflammatori
mediat
tissu
result
demonstr
might
potenti
serv
therapeut
agent
treatment
sever
hfmd
patient
assess
capabl
crossneutr
genotyp
strain
variou
concentr
begin
incub
either
infect
cell
constitut
express
human
viral
genom
infect
cell
detect
rtpcr
reaction
use
primer
specif
target
sequenc
transcript
isol
result
show
inhibit
express
concentrationdepend
manner
quantiti
express
compar
housekeep
gene
phosphat
dehydrogenas
gapdh
shown
bar
graph
fig
investig
protect
efficaci
antibodi
infect
vivo
old
mice
preinfect
pfu
subcutan
sc
follow
administr
isotyp
antibodi
ip
h
post
infect
mice
monitor
sign
develop
daili
basi
mice
treat
isotyp
antibodi
exhibit
visibl
hair
loss
associ
scurfi
skin
peak
day
post
infect
skin
scurfrash
gradual
disappear
day
post
infect
administr
mice
reduc
skin
lesion
rel
mild
degre
day
post
infect
onward
fig
moreov
prechalleng
old
mice
lethal
dose
pfu
caus
progress
limb
paralysi
day
onward
led
death
mice
remain
untreat
isotyp
antibodi
treat
fig
mice
receiv
treatment
h
post
infect
protect
develop
paralysi
subsequ
rescu
lethal
infect
investig
whether
schedul
treatment
ideal
protect
infect
vivo
old
mice
preinfect
sc
lethal
dose
pfu
follow
singl
dose
inject
h
post
infect
follow
dose
inject
first
shot
h
post
infect
follow
anoth
h
later
low
dose
given
h
post
infect
examin
protect
capac
isotyp
antibodi
given
concentr
control
studi
fig
found
mice
better
surviv
rate
correl
shorter
time
interv
administr
post
infect
mice
fulli
protect
given
one
dose
h
post
infect
compar
mice
receiv
h
post
infect
half
mice
die
eighth
day
even
administr
two
dose
later
time
h
post
infect
could
extend
surviv
time
period
eighth
day
post
infect
group
mice
receiv
late
h
treatment
die
infect
condit
approxim
mice
receiv
h
post
infect
surviv
earli
administr
low
dose
h
post
infect
also
provid
protect
infect
earli
administr
might
provid
protect
infect
dose
chosen
follow
patholog
studi
patholog
mice
treat
examin
immunohistochem
histolog
stain
mice
given
isotyp
antibodi
h
post
pfu
infect
antibodytr
anim
sacrif
tissu
section
prepar
day
infect
mark
lesion
inflamm
observ
brain
spinal
cord
skin
heart
spleen
lung
liver
data
shown
infect
mice
receiv
treatment
immunochemistri
stain
antibodi
viral
particl
accumul
brainstem
fig
muscl
fig
mice
treat
contrast
mark
accumul
tissu
mice
receiv
treatment
receiv
isotyp
antibodi
muscl
fiber
damag
nontreat
mice
mice
receiv
isotyp
antibodi
observ
tissu
mice
receiv
compar
section
normal
muscl
tissu
mock
fig
previou
studi
show
microvilli
inner
layer
small
intestin
transgen
mice
would
complet
destroy
infect
investig
whether
pathogenesi
intestin
inhibit
histopatholog
stain
intestin
tissu
day
post
infect
perform
result
show
intestin
mice
receiv
damag
compar
massiv
destruct
mucosa
microvilli
antibodyuntr
isotyp
antibodytr
mice
fig
examin
viral
load
tissu
mice
treat
isol
rna
differ
organ
mice
day
post
infect
quantifi
transcript
use
realtim
rtpcr
notic
administr
reduc
viral
express
significantli
brain
spinal
cord
muscl
skin
intestin
fig
also
confirm
cn
limb
muscletrop
viremia
occur
model
upregul
cn
peripher
tissu
virul
infect
transgen
mice
report
previou
work
also
correspond
clinic
find
increas
patient
higher
express
observ
cn
transgen
mice
infect
may
contribut
recruit
granulocyt
neutrophil
inflamm
brain
cytokin
storm
thu
propos
caus
sever
symptom
administr
intraven
immunoglobulin
ivig
suppress
cytokin
product
use
treat
sever
case
measur
express
proinflammatori
mediat
tissu
mice
receiv
quantit
rtpcr
specif
cytokin
show
express
significantli
reduc
brainstem
spinal
cord
limb
muscl
treatment
fig
express
reduc
brain
limb
muscl
fig
interestingli
elev
shown
spinal
cord
brainstem
muscl
infect
mice
untreat
group
vs
isotypetr
group
treatment
effect
reduc
elev
express
spinal
cord
even
reduc
basal
level
muscl
fig
chemokin
downregul
markedli
cn
limb
muscl
indic
treatment
earli
stage
infect
hinder
viralinduc
pathogenesi
might
affect
lymphocyt
infiltr
inflammatori
tissu
similar
scenario
seen
secret
type
type
ii
interferon
proinflammatori
cytokin
brainstem
spinal
cord
muscl
elev
muscl
brainstem
spinal
cord
muscl
brainstem
muscl
respond
innat
immun
viru
infect
downregul
transgen
mice
receiv
infect
contrast
nontreat
isotyp
antibodytr
mice
fig
express
three
tissu
brainstem
muscl
transgen
mice
also
suppress
significantli
fig
result
indic
protect
mice
develop
pathogenesi
caus
infect
addit
two
genotyp
also
examin
whether
could
protect
mice
coxsacki
viru
infect
one
dose
earli
administr
infect
significantli
prolong
surviv
rescu
mice
develop
neurolog
syndrom
eventu
led
death
fig
result
could
explain
result
weaker
crossneutr
fig
inde
abl
recogn
virion
evid
evalu
bind
use
elisa
protein
interact
fig
western
blot
denatur
protein
interact
fig
contrast
highli
bind
two
strain
show
lower
affin
fig
opposit
antisera
obtain
mice
immun
twice
live
equal
detect
viru
particl
depict
fig
recogn
protein
approxim
kda
approxim
kda
differ
antisera
detect
similar
capsid
protein
pattern
among
isol
highlight
approxim
kda
although
icr
balbcsuckl
mice
report
suscept
genotyp
c
infect
induc
neurolog
patholog
use
mouseadapt
clinic
isol
viru
experi
use
natur
strain
type
iii
interferondefici
newborn
mice
lack
relev
anim
model
hamper
develop
effect
prophylact
therapeut
approach
previous
develop
demonstr
challeng
newborn
mice
b
genotyp
isol
earli
syndrom
hfmd
follow
progress
neurolog
lp
develop
addit
mice
elicit
suscept
report
newborn
mous
model
c
genotyp
infect
result
lethal
neurolog
diseas
despit
muscletrop
viremia
report
model
differ
cnstropism
infect
human
mice
character
bipatholog
tropism
cn
peripher
site
passiv
transfer
protect
antibodi
shown
reduc
sever
viral
infect
includ
japanes
enceph
varicella
coxsackieviru
infect
previous
gener
murin
monoclon
antibodi
crossneutr
subgenogroup
b
isol
vitro
therefor
test
protect
efficaci
neutral
monoclon
antibodi
reliabl
model
show
use
mice
infect
either
genotyp
b
c
virus
protect
develop
hfmdlike
paralyt
symptom
conclud
treatment
earli
stage
h
post
infect
infect
afford
complet
protect
lower
dose
treatment
earli
stage
provid
protect
protect
efficaci
drop
provid
h
post
infect
even
though
multipl
administr
rescu
mice
pathogenesi
suggest
protect
confer
dose
timedepend
manner
sever
larg
epidem
sever
form
infect
young
children
associ
neurolog
diseas
may
occasion
caus
perman
paralysi
death
studi
show
protect
mice
infect
fig
viral
load
differ
tissu
cn
muscl
mice
markedli
reduc
contrast
nontreat
group
fig
result
indic
reduct
viral
load
compart
cn
may
correl
protect
inde
sever
studi
peopl
mice
also
suggest
possibl
immunopathogenesi
clinic
radiolog
laboratori
featur
indic
immunpatholog
result
neurolog
diseas
report
sever
case
elev
level
sever
cytokin
chemokin
report
children
brainstem
enceph
pe
type
type
ii
ifn
found
significantli
elev
mice
treatment
reduct
proinflammatori
mediat
releas
observ
fig
moreov
similar
result
report
clinic
case
level
blood
significantli
decreas
patient
pe
administr
ivig
besid
coxsackievirusinduc
myocard
primarili
attribut
virem
injuri
immun
infiltr
reclam
innat
immun
respons
specif
host
effector
mechan
also
report
involv
cn
coronaviru
infect
collect
result
show
previous
gener
genotyp
monoclon
antibodi
target
linear
epitop
neutral
subgenogroup
strain
vitro
also
abl
crossprotect
genotyp
c
viru
infect
vitro
fig
mous
model
confer
protect
reduct
viral
load
secret
proinflammatori
cytokin
contribut
virem
injuri
immunopathogenesi
contrast
protect
infect
mice
administr
amount
antibodi
protect
mice
lethal
infect
investig
affin
show
lower
reactiv
identifi
specif
recogn
epitop
amino
acid
region
name
encod
residu
genom
comparison
recent
studi
align
highli
conserv
region
amino
acid
sequenc
differ
genotyp
show
dissimilar
may
explain
scenario
fail
crossneutr
due
differ
sequenc
epitop
recogn
also
differ
previou
report
epitop
mous
antisera
gener
peptid
show
strong
stain
neuron
plasma
adult
human
cerebra
fetu
medulla
close
met
peptid
elicit
weak
crossreact
human
tissu
conclus
research
evid
demonstr
crossprotect
efficaci
mice
show
greater
suscept
natur
strain
b
c
orchestr
hfmd
cnslike
syndrom
may
break
limit
current
suckl
model
applic
prolong
time
frame
mice
age
diseas
induct
especi
uniqu
hl
syndrom
model
might
serv
experiment
model
aid
evalu
therapeut
medicin
applic
human
monoclon
antibodi
control
variou
viral
infect
report
therefor
human
expect
serv
therapeut
agent
treat
hfmd
diseas
futur
also
interest
evalu
whether
could
elicit
crossneutr
antibodi
differ
genotyp
model
anim
experi
conduct
accord
guidelin
laboratori
anim
center
nation
health
research
institut
nhri
taiwan
animalus
protocol
review
approv
nhri
institut
anim
care
use
committe
approv
protocol
strain
elicit
lethal
neurolog
virul
hind
limb
paralysi
hlp
induc
hfmdlike
hair
loss
associ
scurf
hl
nonleth
hlp
mice
protect
surviv
rate
use
one
end
point
assess
protect
efficaci
medic
surviv
rate
use
index
pathogenesi
infect
experiment
anim
model
report
mani
studi
challeng
test
score
mice
hl
hlp
perform
investig
weight
loss
occur
test
anim
euthanasia
inhal
minut
follow
cervic
disloc
minim
anim
suffer
perform
viru
challeng
mice
explor
anesthet
inhal
chamber
contain
isofluran
initi
phase
maintainc
phase
minut
subcutan
intraperiton
immun
antibodi
respect
clinic
isol
strain
genotyp
genbank
obtain
taiwan
center
diseas
control
cdc
genotyp
genbank
genbank
one
strain
genbank
provid
professor
jenren
wang
depart
medic
technolog
nation
chen
kung
univers
tainan
taiwan
virus
propag
vero
cell
purifi
previous
describ
monoclon
antibodi
produc
ascet
fluid
purifi
previous
describ
specif
check
western
blot
commerci
mous
isotyp
antibodi
ebiosci
ca
usa
use
control
pcrbase
neutral
assay
adopt
perform
accord
pittlot
et
al
evalu
crossneutr
genotyp
b
c
virus
serial
dilut
mgml
incub
genotyp
b
c
virus
moi
h
mixtur
inocul
monolay
cell
line
plate
h
absorpt
cell
wash
time
pb
rna
extract
use
rneasi
kit
qiagen
ca
usa
follow
instruct
provid
manufactur
two
set
sens
antisens
synthet
oligonucleotid
primer
use
detect
genotyp
b
c
virus
primer
sequenc
use
amplifi
genom
expend
domain
viru
respect
pcr
perform
total
reaction
volum
contain
cdna
pcr
buffer
mm
mm
deoxynucleosid
triphosph
primer
u
faststart
taq
polymeras
roch
usa
amplif
conduct
accord
follow
cycl
program
denatur
min
anneal
elong
min
cycl
follow
final
extens
min
perform
veriti
thermal
cycler
appli
biosystem
usa
pcr
product
separ
electrophoresi
agaros
gel
contain
safe
dna
gel
stain
invitrogen
ny
usa
visual
ultraviolet
light
mice
bred
maintain
previous
describ
old
mice
inocul
pfu
live
pfu
live
viru
isol
subcutan
sc
protect
studi
purifi
neutral
monoclon
antibodi
mgml
inject
intraperiton
ip
mice
h
infect
mice
observ
symptom
develop
day
post
viru
infect
sever
hfmdlike
paralysi
symptom
score
use
follow
criteria
hfmdlike
symptom
hair
loss
associ
scurf
white
spot
hl
hl
hl
hl
hl
hl
back
abdomen
score
degre
paralysi
sever
paralyz
front
rear
limb
movement
rear
limb
moder
paralyz
difficulti
movement
paralyz
rear
limb
bend
leg
mildli
bend
rear
limb
slightli
bend
rear
limb
paralyz
limb
normal
movement
test
anim
euthan
inhal
minut
follow
cervic
disloc
complet
experiment
protocol
weight
loss
occur
accord
guidelin
approv
animalus
protocol
protocol
oneway
anova
kruskalw
test
use
compar
result
obtain
differ
group
hl
paralysi
symptom
unpair
student
test
welch
correct
use
evalu
statist
differ
rna
express
level
group
logrank
test
use
evalu
differ
surviv
pvalu
consid
statist
signific
symbol
use
indic
pvalu
respect
test
perform
use
graphpad
prism
version
window
immunhistochemistri
ihc
perform
paraffinembed
tissu
section
previous
describ
viral
particl
detect
use
murin
monoclon
antibodi
chemicon
intern
follow
visual
use
dab
plu
substrat
kit
zyme
laboratori
histopatholog
stain
conduct
patholog
core
facil
nation
health
research
institut
taiwan
specimen
observ
use
olympu
research
microscop
model
olympu
japan
pictur
manag
use
dp
control
provid
compani
tissu
specif
organ
collect
tube
contain
ml
trizol
reagent
invitrogen
ca
usa
ceram
bead
bertin
technolog
montigni
le
bretonneux
franc
follow
homogen
use
precelli
homogen
bertin
technolog
montigni
le
bretonneux
franc
rna
extract
use
trizol
reagent
follow
instruct
provid
manufactur
puriti
isol
rna
examin
use
spectrophotomet
absorb
ratio
cdna
synthesi
perform
use
transcriptor
first
strand
cdna
synthesi
kit
roch
usa
follow
instruct
provid
manufactur
one
microgram
rna
mix
random
hexam
primer
denatur
min
ad
transcriptor
revers
transcriptas
reaction
buffer
rnase
inhibitor
mm
deoxynucleotid
mix
revers
transcriptas
min
follow
min
result
cdna
subject
quantit
realtim
pcr
analysi
specif
primer
mous
actin
gene
sampl
use
intern
control
evalu
express
cytokin
chemokin
gene
differ
tissu
specifi
primer
pair
use
detect
sequenc
primer
pair
specif
target
gene
previous
note
determin
express
taqman
assay
perform
use
specif
primer
forward
revers
probe
univers
probe
librari
cat
roch
maxima
proberox
qpcr
master
mix
cat
thermo
scientif
use
follow
program
procedur
provid
manufactur
primer
set
synthes
commerci
mission
biotech
taiwan
